Low‐Dose Nivolumab in Various Cancers: A Real‐World Exploratory Analysis in Resource‐Constrained Settings

Subhas Pandit, Simit Sapkota, Abish Adhikari, Jeebana Bhandari, Sunil Shrestha, Rajani Jha, Gerim Prasai, Anjani Kr Jha · 2026

Read Low‐Dose Nivolumab in Various Cancers: A Real‐World Exploratory Analysis in Resource‐Constrained Settings by Subhas Pandit, Simit Sapkota, Abish Adhikari, Jeebana Bhandari, Sunil Shrestha, Rajani Jha, Gerim Prasai, Anjani Kr Jha (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13680289.txt.

Description

Subhas Pandit and colleagues reviewed low-dose nivolumab use in two thousand twenty-six. Nivolumab is an immune therapy that helps fight cancer. Standard doses cost far too much for many patients. Clinics in resource-limited settings use much smaller fixed doses. The team gathered records from patients with varied cancers. Doses were given every three weeks.

Disease control held in about two-thirds of patients. Roughly half showed clear tumor shrinkage. Survival and side effects were tracked over months of follow-up. Results support wider testing of the cheap approach. Lower cost could open treatment to many more people. Careful trials must confirm these early signals.

Catalog record

CREATORSubhas Pandit, Simit Sapkota, Abish Adhikari, Jeebana Bhandari, Sunil Shrestha, Rajani Jha, Gerim Prasai, Anjani Kr Jha
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE20 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13680289

Browse the full library · About the Tower of Babel